CliffBio
small molecule

RETEVMO

SELPERCATINIB

Loss of exclusivityApril 2039latest FDA-listed patent expiry
CompanyELI LILLY AND CO

Drug detail

Brand nameRETEVMO
Active ingredientSELPERCATINIB
Strength80MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2024
Marketing statusRX

Listed patents

PatentExpiresType
12138250*PEDApril 2039—
12138250October 2038use U-3949
10172851*PEDApril 2038—
10137124*PEDApril 2038—
10112942*PEDApril 2038—
10137124October 2037use U-3951
10112942October 2037substance, product
10172851October 2037use U-3951

Regulatory exclusivity

CodeExpires
PEDNovember 2031
ODE*May 2031
PEDMarch 2030
ODE*September 2029
PEDMarch 2028
PEDNovember 2027
M-312September 2027
M-311September 2027
ODE*May 2027

More from ELI LILLY AND CO

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

RETEVMO patent cliff — loss of exclusivity April 2039 | CliffBio